AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 12 - (NewsRx.com & NewsRx.net) -- Ilex Oncology, Inc., (ILXO) announced the initiation of a randomized, double-blind, placebo-controlled phase I/II proof of principle trial to evaluate the effects of Apomine in postmenopausal women with osteoporosis, or low bone mass.
Apomine belongs to a novel class of nonhormonal therapeutic agents known as bisphosphonate esters.
In preclinical studies, the orally available compound Apomine not only prevented breakdown of existing bone (antiresorption effect), but it also demonstrated the ability to stimulate new bone growth (anabolic effect). Current treatment standards are limited to bisphosphonate acids, which prevent bone resorption. In addition, injectable anabolic agents, which build ...
Source: HighBeam Research, Apomine trial started in postmenopausal women.(Brief Article)